[Tolerance profile of platinum compounds].
Cascinu
S
S
Oncologia Medica, Azienda Ospedaliera, Parma.
Munaó
S
S
Mare
M
M
Amadio
P
P
Crucitta
E
E
Picone
G
G
D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D005440:Fluid Therapy; D006801:Humans; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D017671:Platinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced / Q000517:prevention & control
D009944:Organoplatinum Compounds; D017671:Platinum Compounds; D000077150:Oxaliplatin; D016190:Carboplatin; D002945:Cisplatin; C049777:ormaplatin